$KNSA
Kiniksa Pharmaceuticals Ltd

2024 Q3 Form 10-Q Financial Statement

#000155837024013840 Filed on October 29, 2024

View on sec.gov

Income Statement

Concept 2024 Q3
Revenue $112.2M
YoY Change 67.37%
Cost Of Revenue $20.11M
YoY Change 121.27%
Gross Profit $92.11M
YoY Change 58.92%
Gross Profit Margin 82.08%
Selling, General & Admin $46.40M
YoY Change 34.61%
% of Gross Profit 50.38%
Research & Development $26.06M
YoY Change 52.33%
% of Gross Profit 28.29%
Depreciation & Amortization $87.00K
YoY Change -70.21%
% of Gross Profit 0.09%
Operating Expenses $72.46M
YoY Change 40.49%
Operating Profit -$9.658M
YoY Change -11.61%
Interest Expense $2.457M
YoY Change 1.11%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$7.201M
YoY Change -15.27%
Income Tax $5.492M
% Of Pretax Income
Net Earnings -$12.69M
YoY Change -8.39%
Net Earnings / Revenue -11.31%
Basic Earnings Per Share -$0.18
Diluted Earnings Per Share -$0.18
COMMON SHARES
Basic Shares Outstanding 71.73M
Diluted Shares Outstanding 71.73M

Balance Sheet

Concept 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $223.8M
YoY Change 8.07%
Cash & Equivalents $97.38M
Short-Term Investments $126.4M
Other Short-Term Assets $33.95M
YoY Change 28.61%
Inventory $28.68M
Prepaid Expenses
Receivables $24.89M
Other Receivables $0.00
Total Short-Term Assets $311.3M
YoY Change 21.55%
LONG-TERM ASSETS
Property, Plant & Equipment $561.0K
YoY Change -38.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.853M
YoY Change 242.33%
Total Long-Term Assets $244.0M
YoY Change 7.51%
TOTAL ASSETS
Total Short-Term Assets $311.3M
Total Long-Term Assets $244.0M
Total Assets $555.3M
YoY Change 14.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.328M
YoY Change 722.92%
Accrued Expenses $40.38M
YoY Change -1.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $95.96M
YoY Change 79.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $1.962M
YoY Change 0.87%
Total Long-Term Liabilities $1.962M
YoY Change 0.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $95.96M
Total Long-Term Liabilities $1.962M
Total Liabilities $118.3M
YoY Change 51.78%
SHAREHOLDERS EQUITY
Retained Earnings -$512.3M
YoY Change 1.8%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $437.0M
YoY Change
Total Liabilities & Shareholders Equity $555.3M
YoY Change 14.95%

Cashflow Statement

Concept 2024 Q3
OPERATING ACTIVITIES
Net Income -$12.69M
YoY Change -8.39%
Depreciation, Depletion And Amortization $87.00K
YoY Change -70.21%
Cash From Operating Activities -$2.236M
YoY Change -113.16%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$6.348M
YoY Change -48.22%
Cash From Investing Activities -$6.348M
YoY Change -48.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.689M
YoY Change 1116.18%
NET CHANGE
Cash From Operating Activities -2.236M
Cash From Investing Activities -6.348M
Cash From Financing Activities 6.689M
Net Change In Cash -1.895M
YoY Change -135.96%
FREE CASH FLOW
Cash From Operating Activities -$2.236M
Capital Expenditures $0.00
Free Cash Flow -$2.236M
YoY Change -113.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 knsa Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q4 knsa Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
dei Entity Central Index Key
EntityCentralIndexKey
0001730430
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38492
dei Entity Registrant Name
EntityRegistrantName
Kiniksa Pharmaceuticals International, plc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
dei Entity Address Address Line1
EntityAddressAddressLine1
23 Old Bond Street, Floor 3
dei Entity Address City Or Town
EntityAddressCityOrTown
London
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
WIS 4PZ
dei Entity Address Country
EntityAddressCountry
GB
dei City Area Code
CityAreaCode
(781)
dei Local Phone Number
LocalPhoneNumber
431-9100
dei Entity Information Former Legal Or Registered Name
EntityInformationFormerLegalOrRegisteredName
Kiniksa Pharmaceuticals, Ltd.
dei Security12b Title
Security12bTitle
Class A Ordinary Shares
dei Trading Symbol
TradingSymbol
KNSA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97376000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
107954000
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
126404000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
98417000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24888000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21266000
CY2024Q3 us-gaap Inventory Net
InventoryNet
28680000
CY2023Q4 us-gaap Inventory Net
InventoryNet
31122000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
33953000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
17538000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
311301000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
276297000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
561000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
734000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11095000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11931000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7853000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
827000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
16500000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
17250000
CY2024Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
207988000
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
219283000
CY2024Q3 us-gaap Assets
Assets
555298000
CY2023Q4 us-gaap Assets
Assets
526322000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
8328000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8246000
CY2024Q3 knsa Accrued Collaboration Expenses Current
AccruedCollaborationExpensesCurrent
29148000
CY2023Q4 knsa Accrued Collaboration Expenses Current
AccruedCollaborationExpensesCurrent
16939000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40379000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27728000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
307000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2031000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2253000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
16069000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
8193000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
95955000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
63666000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
11811000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
11954000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8564000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10005000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1962000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1858000
CY2024Q3 us-gaap Liabilities
Liabilities
118292000
CY2023Q4 us-gaap Liabilities
Liabilities
87483000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
949282000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
916763000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-41000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-512255000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-477950000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
437006000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
438839000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
555298000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
526322000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
112214000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
67046000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
300703000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
186864000
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
20109000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9088000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
43014000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
23823000
CY2024Q3 knsa Collaboration Expenses
CollaborationExpenses
29307000
CY2023Q3 knsa Collaboration Expenses
CollaborationExpenses
17311000
knsa Collaboration Expenses
CollaborationExpenses
80122000
knsa Collaboration Expenses
CollaborationExpenses
39585000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26057000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17106000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
76408000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56045000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
46399000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34468000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
127476000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
92688000
CY2024Q3 knsa Total Cost Of Revenue And Operating Expenses
TotalCostOfRevenueAndOperatingExpenses
121872000
CY2023Q3 knsa Total Cost Of Revenue And Operating Expenses
TotalCostOfRevenueAndOperatingExpenses
77973000
knsa Total Cost Of Revenue And Operating Expenses
TotalCostOfRevenueAndOperatingExpenses
327020000
knsa Total Cost Of Revenue And Operating Expenses
TotalCostOfRevenueAndOperatingExpenses
212141000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9658000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10927000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26317000
us-gaap Operating Income Loss
OperatingIncomeLoss
-25277000
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2457000
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2428000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
7144000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
6175000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7201000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8499000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19173000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19102000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5492000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5356000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15132000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7949000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12693000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13855000
us-gaap Net Income Loss
NetIncomeLoss
-34305000
us-gaap Net Income Loss
NetIncomeLoss
-11153000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71726685
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71726685
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70186016
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70186016
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71123658
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71123658
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69953591
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69953591
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12693000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13855000
us-gaap Net Income Loss
NetIncomeLoss
-34305000
us-gaap Net Income Loss
NetIncomeLoss
-11153000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
89000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-47000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-45000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
89000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-14000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-47000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-45000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12604000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13869000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34352000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11198000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
438839000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
3613000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7206000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-59000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-17704000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
431895000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
-178000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7363000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-77000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3908000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
435095000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
6689000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7826000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
89000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12693000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
437006000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
396149000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
90000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6115000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-12270000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
390095000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
158000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6473000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-42000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
14972000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
411656000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
552000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6788000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13855000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
405127000
us-gaap Profit Loss
ProfitLoss
-34305000
us-gaap Profit Loss
ProfitLoss
-11153000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1295000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1801000
us-gaap Share Based Compensation
ShareBasedCompensation
22395000
us-gaap Share Based Compensation
ShareBasedCompensation
19376000
knsa Noncash Lease Expense
NoncashLeaseExpense
2369000
knsa Noncash Lease Expense
NoncashLeaseExpense
2317000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
378000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
772000
knsa Gain On Sale Of Property Plant Equipment
GainOnSaleOfPropertyPlantEquipment
25000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-175000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
11295000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-8079000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
16509000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15912000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3622000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9619000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2442000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3984000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-7656000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
7211000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-3178000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-22000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6887000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
32736000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
11654000
knsa Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3196000
knsa Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2555000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-450000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2436000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
104000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
106000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6919000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
8976000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
25000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
84000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
74000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
180020000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
144116000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
152458000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
129527000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27621000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14663000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
14530000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2744000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4406000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1944000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10124000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
800000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-10578000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4887000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
107954000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122715000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
97376000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117828000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
741000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
6917000
knsa Change In Right Of Use Asset New Modified And Terminated Leases
ChangeInRightOfUseAssetNewModifiedAndTerminatedLeases
1533000
knsa Change In Right Of Use Asset New Modified And Terminated Leases
ChangeInRightOfUseAssetNewModifiedAndTerminatedLeases
9600000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
201000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
59000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reclassifications </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations and comprehensive loss or cash flows. A </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reclassification has been made to the Consolidated Balance Sheet for fiscal year ended December 31, 2023, to reclassify the collaboration accrued expenses to be a separate line item.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of revenue, the accrual for research and development expenses, and the valuation of our deferred tax assets. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p>
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-512255000
us-gaap Net Income Loss
NetIncomeLoss
-34305000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6919000
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
223780000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q3 knsa Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2023Q4 knsa Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
126326000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
80000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
126404000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
100382000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
30000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
100412000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2024Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q4 knsa Product Revenue Reserve For Contractual Adjustments
ProductRevenueReserveForContractualAdjustments
2022000
CY2023Q4 knsa Product Revenue Reserve For Government Rebates
ProductRevenueReserveForGovernmentRebates
3775000
CY2023Q4 knsa Product Revenue Reserve For Sales Returns
ProductRevenueReserveForSalesReturns
341000
CY2023Q4 knsa Product Revenue Reserves And Allowances
ProductRevenueReservesAndAllowances
6138000
knsa Product Revenue Provision For Contractual Adjustments
ProductRevenueProvisionForContractualAdjustments
17228000
knsa Product Revenue Provision For Government Rebates
ProductRevenueProvisionForGovernmentRebates
13222000
knsa Product Revenue Provision For Product Returns
ProductRevenueProvisionForProductReturns
916000
knsa Product Revenue Provision For Reserves And Allowances
ProductRevenueProvisionForReservesAndAllowances
31366000
knsa Product Revenue Contractual Adjustments Prior Years Sales
ProductRevenueContractualAdjustmentsPriorYearsSales
31000
knsa Product Revenue Government Rebates Adjustments Prior Years Sales
ProductRevenueGovernmentRebatesAdjustmentsPriorYearsSales
155000
knsa Product Revenue Returns Adjustments Prior Year Sales
ProductRevenueReturnsAdjustmentsPriorYearSales
-836000
knsa Product Revenue Adjustments For Reserves And Allowances Prior Year Sales
ProductRevenueAdjustmentsForReservesAndAllowancesPriorYearSales
-650000
knsa Product Revenue Refunds On Contractual Adjustments
ProductRevenueRefundsOnContractualAdjustments
15849000
knsa Product Revenue Refunds And Payments On Government Rebates
ProductRevenueRefundsAndPaymentsOnGovernmentRebates
4538000
knsa Product Revenue Refunds And Credits For Reserves And Allowances
ProductRevenueRefundsAndCreditsForReservesAndAllowances
20387000
knsa Product Revenue Contractual Adjustments Payments And Sales Returns Prior Year Sales
ProductRevenueContractualAdjustmentsPaymentsAndSalesReturnsPriorYearSales
1957000
knsa Product Revenue Government Rebates Payments And Sales Returns Prior Year Sales
ProductRevenueGovernmentRebatesPaymentsAndSalesReturnsPriorYearSales
3620000
knsa Product Revenue Refunds On Product Returns Prior Year Sales
ProductRevenueRefundsOnProductReturnsPriorYearSales
192000
knsa Product Revenue Refunds And Credits For Reserves And Allowances Prior Year Sales
ProductRevenueRefundsAndCreditsForReservesAndAllowancesPriorYearSales
5769000
CY2024Q3 knsa Product Revenue Reserve For Contractual Adjustments
ProductRevenueReserveForContractualAdjustments
1413000
CY2024Q3 knsa Product Revenue Reserve For Government Rebates
ProductRevenueReserveForGovernmentRebates
8684000
CY2024Q3 knsa Product Revenue Reserve For Sales Returns
ProductRevenueReserveForSalesReturns
1901000
CY2024Q3 knsa Product Revenue Reserves And Allowances
ProductRevenueReservesAndAllowances
11998000
CY2024Q3 knsa Product Revenue Reserves And Allowances
ProductRevenueReservesAndAllowances
11998000
CY2023Q4 knsa Product Revenue Reserves And Allowances
ProductRevenueReservesAndAllowances
6138000
CY2024Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
10159000
CY2024Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
12143000
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
18258000
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
11325000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
12864000
CY2024Q3 knsa Inventory Current And Noncurrent Net
InventoryCurrentAndNoncurrentNet
33627000
CY2023Q4 knsa Inventory Current And Noncurrent Net
InventoryCurrentAndNoncurrentNet
31122000
CY2024Q3 knsa Inventory Current And Noncurrent Net
InventoryCurrentAndNoncurrentNet
33627000
CY2023Q4 knsa Inventory Current And Noncurrent Net
InventoryCurrentAndNoncurrentNet
31122000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8666000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8519000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8105000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7785000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
561000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
734000
CY2024Q3 us-gaap Depreciation
Depreciation
87000
CY2023Q3 us-gaap Depreciation
Depreciation
292000
us-gaap Depreciation
Depreciation
360000
us-gaap Depreciation
Depreciation
873000
CY2024Q3 knsa Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
14174000
CY2023Q4 knsa Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
7895000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13081000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15954000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
12615000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3553000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
509000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
326000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40379000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27728000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7826000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6788000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22395000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19376000
CY2017Q3 knsa Time Period To Terminate Agreement By Both Parties Under Uncured Material Breaches
TimePeriodToTerminateAgreementByBothPartiesUnderUncuredMaterialBreaches
P90D
CY2017Q3 knsa Time Period To Terminate Agreement Under Payment Related Breaches
TimePeriodToTerminateAgreementUnderPaymentRelatedBreaches
P30D
CY2017Q3 knsa Consecutive Suspension Of Activities Period To Terminate Agreement
ConsecutiveSuspensionOfActivitiesPeriodToTerminateAgreement
P12M
CY2017Q3 knsa Time Period To Terminate Agreement After Eighteen Months Of Agreement
TimePeriodToTerminateAgreementAfterEighteenMonthsOfAgreement
P1Y
CY2017Q3 knsa Time Period To Terminate Agreement If Products Are Determined To Have Certain Safety Concerns
TimePeriodToTerminateAgreementIfProductsAreDeterminedToHaveCertainSafetyConcerns
P3M
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12693000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13855000
us-gaap Net Income Loss
NetIncomeLoss
-34305000
us-gaap Net Income Loss
NetIncomeLoss
-11153000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71726685
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71726685
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70186016
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70186016
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71123658
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71123658
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69953591
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69953591
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14055982
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13973801
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14055982
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13973801
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2024Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5492000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15132000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5356000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7949000
CY2024Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
186893000
CY2024Q3 knsa Purchase Commitment Obligation Due In Next Rolling Twelve Months
PurchaseCommitmentObligationDueInNextRollingTwelveMonths
60731000

Files In Submission

Name View Source Status
0001558370-24-013840-index-headers.html Edgar Link pending
0001558370-24-013840-index.html Edgar Link pending
0001558370-24-013840.txt Edgar Link pending
0001558370-24-013840-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
knsa-20240930.xsd Edgar Link pending
knsa-20240930x10q.htm Edgar Link pending
knsa-20240930xex10d1.htm Edgar Link pending
knsa-20240930xex31d1.htm Edgar Link pending
knsa-20240930xex31d2.htm Edgar Link pending
knsa-20240930xex32d1.htm Edgar Link pending
knsa-20240930xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
knsa-20240930_cal.xml Edgar Link unprocessable
knsa-20240930_lab.xml Edgar Link unprocessable
knsa-20240930_pre.xml Edgar Link unprocessable
knsa-20240930x10q_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
knsa-20240930_def.xml Edgar Link unprocessable